TMO
A cleaner pulse check for the lab economy
Thermo Fisher just handed investors a pretty cheerful update: Q2 adjusted EPS came in at $6.03, topping Wall Street’s $5.71, while revenue hit $11.994 billion and beat estimates too. Not bad for a company that sells the picks and shovels behind a lot of biotech and pharma work.
The bigger story, though, is the vibe shift. Management said customer activity is strengthening across end markets — which is corporate-speak for “people are spending again, and we like what we see.” That mattered enough to send the stock up 9.05% to $574.09 on Thursday.
Where the growth came from
The quarter wasn’t just one big blob of green. Thermo Fisher said:
- Life Sciences Solutions sales rose 12.6%
- Analytical Instruments climbed 6.9%
- Specialty Diagnostics grew 6.3%
- Laboratory Products and Biopharma Services jumped 11.6%
Pharma and biotech led the charge with mid-single-digit growth, while academic/government and industrial markets also moved higher. Translation: this wasn’t a one-segment fluke. The engine is firing in a few different rooms.
Guidance got a bump, too
If earnings are the appetizer, guidance is the main course. Thermo Fisher raised 2026 adjusted EPS guidance to $24.93-$25.33 from $24.64-$25.12, and lifted sales guidance to $47.40 billion-$48.10 billion. The company now expects revenue growth to land around 4%, with the upper end of its prior range looking a lot more realistic.
CEO Marc Casper also noted the company has an active M&A pipeline, which is a polite way of saying Thermo Fisher still has plenty of appetite to go shopping in its fragmented industry. Big picture: when a company like Thermo Fisher says customers are loosening up, that’s a useful read-through for the broader life-sciences toolkit trade.